Hemostemix Inc.

TSXV:HEM.V

$0.075 CAD

-$0.01 (-11.76%)

Volume
71.88K
Average Volume
172.76K
Market Capitalization
$10.54M
P/E Ratio
-3.38
Dividend Yield
0.00%
Price Target
$
Year High
$0.11
Year Low
$0.04
Payout Ratio
$0.00
Current Ratio
$0.07

Industry, Sector & symbol

Stock Exchange Toronto Stock Exchange Ventures
CEO Mr. Thomas A. Smeenk B.A., BA Hons
Industry Biotechnology
Sector Healthcare
Current Symbol HEM.V
CUSIP None
CIK None
Web https://www.hemostemix.com
Phone 905-580-4170
Currency CAD
Employees None
Country CA

Liquidity

Debt-to-Equity Ratio -0.55
Payout Ratio 0.00
Current Ratio 0.07
Quick Ratio 0.07
Cash Ratio 0.03

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow 0.00
Price / Cash Flow -29.41
Price / Book -0.78

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.0303
Trailing P/E Ratio -3.38
PEG Ratio 0.27
P/E Growth 0.27
Net Income $-2.5M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity 25.45%
Return on Assets -794.05%

Financials Score

AltmanZ Score -401.98
Piotroski Score 1.00
Working Capital -3.25M
Total Assets 243.78K
Ebit -1.3M
Market Cap 10.54M
Total Liabilities 8.6M

Poll Results

About Hemostemix Inc. (TSXV:HEM.V) Stock

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada. ...

Frequently Asked Questions

What is the current Hemostemix Inc. (HEM.V) stock price?

Hemostemix Inc.(TSXV:HEM.V) stock price is $0.075 in the last trading session. During the trading session, HEM.V stock reached the peak price of $0.11 while $0.035 was the lowest point it dropped to. The percentage change in HEM.V stock occurred in the recent session was --11.76% while the dollar amount for the price change in HEM.V stock was -$-0.01.

HEM.V's industry and sector of operation?

The TSXV listed HEM.V is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of HEM.V?

Mr. Peter Pavlin | Vice President of Operations
Ms. Christina Wu CPA | Interim Chief Financial Officer
Mr. Thomas A. Smeenk B.A., BA Hons | Co-Founder, President, Chief Executive Officer & Director
Dr. Fraser C. Henderson Sr., M.D. | Chief Medical Officer
|

How many employees does HEM.V have?

Number of HEM.V employees currently stands at None. HEM.V operates from 707-7th Avenue SW, Calgary, AB T2P 3H6, CA.

Link for HEM.V official website?

Official Website of HEM.V is: https://www.hemostemix.com

How do I contact HEM.V?

HEM.V could be contacted at phone #905-580-4170 and can also be accessed through its website. HEM.V operates from 707-7th Avenue SW, Calgary, AB T2P 3H6, CA.

How many shares of HEM.V are traded daily?

The average number of HEM.V shares traded daily for last 3 months was 172.76K.

What is the market cap of HEM.V currently?

The market value of HEM.V currently stands at $10.54M with its latest stock price at $0.075